Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

BNP Paribas Exane initiated coverage of Sanofi (SNY) with an Outperform rating and $65 price target Stay Ahead of the Market: Discover ...

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report) and HealthStream (HSTM – Research Report) with neutral ratings, ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of major European drugmakers fell Wednesday morning after U.S. President Donald Trump reaffirmed plans to impose a ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life ... career she has held senior leadership roles at GlaxoSmithKline (GSK), Sanofi and Bausch Health. Ms.